Biomedical Engineering Reference
In-Depth Information
De Caterina AR, Leone AM. Why beta-blockers should not be used as first choice in uncomplicated
hypertension. Am J Cardiol 2010;105:1433-8.
Dotter CT, Rosch J, Seaman AJ. Selective clot lysis with low-dose streptokinase. Radiology
1974;111:31-7.
Faber MJ, Agnetti G, Bezstarosti K, et al. Recent developments in proteomics: implications for
the study of cardiac hypertrophy and failure. Cell Biochem Biophys 2006;44:11-29.
Grygier M, Araszkiewicz A, Lesiak M, et al. New Method of Intracoronary Adenosine Injection
to Prevent Microvascular Reperfusion Injury in Patients With Acute Myocardial Infarction
Undergoing Percutaneous Coronary Intervention. Am J Cardiol 2011 Feb 9; doi:10.1016/j.
amjcard.2010.12.010.
Gucek M, Murphy E. What can we learn about cardioprotection from the cardiac mitochondrial
proteome? Cardiovasc Res 2010;88:211-8.
Herity NA, Lo ST, Oei F, et al. Selective regional myocardial infiltration by the percutaneous coro-
nary venous route: A novel technique for local drug delivery. Catheter Cardiovasc Interv
2000;51:358-63.
Izumiya Y, Kojima S, Kojima S, et al. Long-term use of oral nicorandil stabilizes coronary plaque
in patients with stable angina pectoris. Atherosclerosis 2011;214:415-21.
Jain KK. Proteomics: technologies, markets and companies. Jain PharmaBiotech, Basel, 2011.
Jennings RB, Sommers HM, Smyth GA, et al. Myocardial necrosis induced by temporary occlu-
sion of a coronary artery in the dog. Arch Pathol 1960;70:68-78.
Kanashiro-Takeuchi RM, Tziomalos K, Takeuchi LM, et al. Cardioprotective effects of growth
hormone-releasing hormone agonist after myocardial infarction. PNAS 2010;107:2604-9.
Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol Efflux Capacity, High-Density
Lipoprotein Function, and Atherosclerosis. N Engl J Med 2011; 364:127-35.
Kroon PA, Iyer A, Chunduri P, et al. The cardiovascular nutrapharmacology of resveratrol: phar-
macokinetics, molecular mechanisms and therapeutic potential. Curr Med Chem
2010;17:2442-55.
Marsh N, Marsh A. A short history of nitroglycerine and nitric oxide in pharmacology and physi-
ology. Clin Exp Pharmacol Physiol 2000;27:313-9.
Metra M, Bugatti S, Bettari L, et al. Can we improve the treatment of congestion in heart failure?
Expert Opin Pharmacother 2011 February 23; doi: 10.1517/14656566.2011.557069.
Murrell W. Nitroglycerine as a remedy for angina pectoris. Lancet 1879;1:80-1, 113-5, 151-2,
225-7.
Nicholls SJ, Uno K, Kataoka Y, Nissen SE. ETC-216 for coronary artery disease. Expert Opin
Biol Ther 2011;11:387-94.
Parikh D, Juergens CP. Abciximab as an adjunctive therapy for patients undergoing percutaneous
coronary interventions. Expert Opin Biol Ther 2011;11:235-46.
Patel JA, Ghatak SB. Pexelizumab and its role in the treatment of myocardial infarction and in
coronary artery bypass graft surgery: a review. Recent Patents Cardiovasc Drug Discov
2008;3:145-52.
Perlman DH, Bauer SM, Ashrafian H, et al. Mechanistic insights into nitrite-induced cardiopro-
tection using an integrated metabolomic/proteomic approach. Circ Res 2009;104:796-804.
Sade RM, Fitzharris TP. Myocyte transplantation for treatment of complete heart block. Surgery
1985;97:495-7.
Suzuki JI, Ogawa M, Itai A, et al. Effects of specific chemical suppressors of plasminogen activa-
tor inhibitor-1 in cardiovascular diseases. Expert Opin Invest Drugs 2011;20:255-264.
Turer AT, Hill JA. Pathogenesis of myocardial ischemia-reperfusion injury and rationale for
therapy. Am J Cardiol 2010;106:360-8.
Yogaratnam JZ, Laden G, Guvendik L, et al. Pharmacological preconditioning with hyperbaric
oxygen: can this therapy attenuate myocardial ischemic reperfusion injury and induce myocar-
dial protection via nitric oxide? J Surg Res 2008;149:155-64.
Zhang J, Liem DA, Mueller M, et al. Altered proteome biology of cardiac mitochondria under
stress conditions. J Proteome Res 2008;7:2204-14.
Search WWH ::
Custom Search